Brain Cancer Survival Improved Following FDA Approval of Bevacizumab, Mayo Study Finds

A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer.
Source: Mayo Clinic Research News - Category: Research Authors: Source Type: news